Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1

NEW YORK (GenomeWeb) – Vermillion said today that CareFirst BlueCross BlueShield (BCBS) has agreed to cover its OVA1 ovarian cancer test.

CareFirst BCBS covers more than 3 million patients in Maryland, Washington DC, and Virginia.

"This is our fourth recent announcement of new managed care contracts as we continue to expand our reach in our key strategic market areas," Valerie Palmieri, Vermillion's president and CEO said in a statement. Most recently, the company signed an agreement in July with Michigan healthcare insurance company Priority Health Managed Benefits.

OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.